With a market capitalization (market cap) of $333.87B — a measure of how much the company is worth — Merck & Co., Inc. is the 41st most valuable company in Healthcare as of August 18, 2026. Shares trade at $135.18, down +0.58% on the day.
of 2,587
price ÷ annual EPS
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring. Merck's extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.
Visit websiteAs of August 18, 2026, Merck & Co., Inc. (MRK) is worth $333.87B — this is its market capitalization, the total value of all its outstanding shares.
Merck & Co., Inc.’s market cap is $333.87B, which ranks it #41 among the most valuable companies in the Healthcare sector tracked on MarketCapLens.
Merck & Co., Inc. (MRK) shares trade at $135.18, down 0.58% on the day, as of August 18, 2026.
Merck & Co., Inc. trades at a price-to-earnings (P/E) ratio of 18.5, based on its latest share price and annual earnings per share.
Fundamentals are annual. Figures labeled with their fiscal year.
FY 2025